Alfred Hartojo
Alfred Hartojo is a current PhD candidate at the University of Sydney’s Bacterial Outer Membrane Biogenesis lab under the supervision of Dr. Matthew Thomas Doyle. His research focuses on developing novel surface-acting therapeutics to combat Gram-negative bacterial infections by bridging generative AI protein design, in silico and traditional drug screening, high-throughput assay development, and molecular and structural biology techniques. This resulted in the development of the world’s first-in-class inhibitor of the Gram-negative bacterial two-partner and understand it’s mechanism of action. His work is IP-protected (PCT/AU2025/050953).
Before this, Alfred completed an undergraduate degree in medical science and medicinal chemistry, and a first-class Honours degree at the University of Sydney under the supervision of Dr. Matthew Thomas Doyle. He also completed a Diploma degree in pharmaceutical science at Ngee Ann Polytechnic in Singapore.
Abstracts this author is presenting:
